The Claim
In adults with nonalcoholic fatty liver disease who are treated with GLS at a dose of 8.12 g/day for 12 weeks, the degree of reduction in gamma-glutamyl transferase (GGT) and waist circumference is positively correlated with the reduction in serum fibroblast growth factor 21 (FGF-21), with correlation coefficients of r = 0.374 and r = 0.343 respectively, indicating that changes in FGF-21 levels may reflect improvements in liver and metabolic health.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If you have fatty liver and take a supplement called GLS for 12 weeks, the more your FGF-21 levels go down, the more your liver enzyme and belly size tend to improve — suggesting this protein might be a marker for better liver and metabolic health.
See the scientific wording
In adults with nonalcoholic fatty liver disease treated with GLS (8.12 g/day) for 12 weeks, the magnitude of reduction in gamma-glutamyl transferase (GGT) and waist circumference is positively correlated with the reduction in serum fibroblast growth factor 21 (FGF-21), with correlation coefficients of r = 0.374 and r = 0.343 respectively, suggesting that FGF-21 changes may reflect improvements in liver and metabolic health.
What the research says
1 studyThe study tested the same supplement and found that as liver enzyme levels and waist size improved, so did a blood marker linked to liver health, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.